Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

TL;DR: Recent data on DITMA is summarized, categorizing drugs based on mechanisms of actions and specialties, and novel reports have unraveled potential new mechanisms that might contribute to a targeted therapy of this syndrome.

TL;DR: daclizumab, as add-on or monotherapy in relapsing–remitting MS, was highly effective in reducing relapse rate, disability progression, and the number and volume of gadolinium-enhancing, T1 and T2 lesions on brain magnetic resonance imaging (MRI), and reproduced the expansion of CD56bright NK cells as a biomarker for daclizuab activity.

TL;DR: This Rapid Review, which summarises emerging injectable therapies for relapsing-remitting MS, and discusses pharmacological mechanisms, clinical trials, adverse events, and use in clinical practice, concludes that further clarification of purported mechanisms of action and continued surveillance will be essential to establish the safety and clinical efficacy of these drugs.

TL;DR: This review provides an overview on calcium channels in neurons and glial cells and summarizes several approaches that have been and are currently being tested for their neuroprotective capacities in MS.

TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.

TL;DR: In this article, the authors derived the asymptotic distribution of the maximum partial likelihood estimator β for the vector of regression coefficients β under a possibly misspecified Cox proportional hazards model.

TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.

TL;DR: The history of clinical diagnostic criteria demonstrates the evolution from rather tentative classifications of restricted value to the more elaborate 1983 scheme which incorporates some laboratory procedures under the rubric paraclinical tests as well as a new category based on the presence of specific abnormalities of the cerebrospinal fluid (CSF).